Entera Bio Price to Sales Ratio 2018-2021 | ENTX

Historical PS ratio values for Entera Bio (ENTX) over the last 10 years. The current P/S ratio for Entera Bio as of November 29, 2021 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Entera Bio P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2021-11-29 3.39 119.50
2021-09-30 4.71 $0.03 166.03
2021-06-30 5.98 $0.03 228.11
2021-03-31 3.81 $0.02 154.52
2020-12-31 1.08 $0.02 54.51
2020-09-30 1.24 $0.02 76.06
2020-06-30 1.84 $0.02 99.15
2020-03-31 2.06 $0.02 93.52
2019-12-31 2.14 $0.02 108.74
2019-09-30 2.49 $0.04 57.71
2019-06-30 3.43 $0.04 89.87
2019-03-31 4.33 $0.03 135.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.081B $0.000B
Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09